Eric Andreansky successfully defended his dissertation, “Synthetic Studies Toward Methanoquinolizidine-Containing Akuammiline Alkaloids” on Wednesday, April 26th, 2017. Eric’s committee was led by Simon Blakey with Frank McDonald and Lanny Liebeskind as additional members.
Deal of 2015:Bristol-Myers Squibb – CXCR4 Antagonists
Dennis Liotta (chemistry) and Lawrence Wilson and Michael Natchus (Emory Institute for Drug Discovery)
CXCR4 protein expression is low or absent in many healthy tissues, but it was shown to be expressed in more than 20 types of cancer, including prostate, ovarian and breast cancer, and melanoma. Emory researchers have developed small molecules that act as antagonists to CXCR4 and may be orally administered.
CXCR4 antagonists are known to block adhesion, replication and outgrowth of HIV and can mobilize white blood cells. In 2015, Emory executed a high net worth license for the technology and research collaboration with Bristol-Myers Squibb.
Innovation of 2015:Motion-based Detection by DNA Machines
Khalid Salaita (chemistry)
Single Nucleotide Polymorphism (SNP) genotyping is the screening and analysis of genetic variations of SNPs, which are common in all species including humans. SNP genotyping and analysis technology can analyze thousands of SNPs and has the potential for whole-genome genotyping. DNA-based machines have potential in several applications and industries, but DNA machines called “walkers” are challenging to work with due to their low fidelity and slow rates.
Emory inventors have developed a DNA-based machine that converts chemical energy into controlled motion. Because these DNA-based machines “roll” rather than “walk,” they are able to surpass the maximum speed of existing DNA motors by three orders of magnitude. This technology can serve as a new and powerful tool in SNP genotyping, as well as other applications in diagnostics, drug delivery and biomaterials.